Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer
Abstract Background Circulating tumor DNA (ctDNA) has potential as a specific, noninvasive, and cost‐effective new biomarker for patients with lung cancer. This study aimed to determine whether plasma ctDNA can be used to predict treatment outcomes in patients with lung cancer. Methods Pre‐ and in‐t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14230 |
| _version_ | 1818202560655261696 |
|---|---|
| author | Min Zhang Chao Huang Huan Zhou Dan Liu Runze Chen Xiuhua Li Ye Cheng Bing Gao Jun Chen |
| author_facet | Min Zhang Chao Huang Huan Zhou Dan Liu Runze Chen Xiuhua Li Ye Cheng Bing Gao Jun Chen |
| author_sort | Min Zhang |
| collection | DOAJ |
| description | Abstract Background Circulating tumor DNA (ctDNA) has potential as a specific, noninvasive, and cost‐effective new biomarker for patients with lung cancer. This study aimed to determine whether plasma ctDNA can be used to predict treatment outcomes in patients with lung cancer. Methods Pre‐ and in‐treatment blood samples were collected from 14 patients with lung cancer receiving chemotherapy. Based on next‐generation sequencing technology, we constructed a unique molecular identifier (UMI) library and performed targeted deep sequencing of 72 genes (15 000×). We used dVAF to evaluate the change level and trend of variant allele frequency (VAF). Results We identified MUC16, KMT2D, AMER1, and NTRK1 as the most‐frequently mutated genes in ctDNA associated with lung cancer. Furthermore, we showed that the change trend of dVAF in patients with lung cancer undergoing chemotherapy was closely related to the changes in both tumor volume and tumor biomarkers, including CEA, CA125, NSE, and CK (Cytokeratin). Moreover, the ctDNA analysis revealed disease progression of SCLC patients earlier than did computed tomography. Conclusions The dynamic detection of plasma ctDNA VAF has the potential value as a biomarker for evaluating the efficacy of chemotherapy in patients with SCLC and advanced NSCLC, and may predict the progression of lung cancer patients earlier than radiography. |
| first_indexed | 2024-12-12T03:11:24Z |
| format | Article |
| id | doaj.art-f4bee13baeab4e77af65c34235871ebe |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-12T03:11:24Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-f4bee13baeab4e77af65c34235871ebe2022-12-22T00:40:23ZengWileyThoracic Cancer1759-77061759-77142022-01-011319510610.1111/1759-7714.14230Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancerMin Zhang0Chao Huang1Huan Zhou2Dan Liu3Runze Chen4Xiuhua Li5Ye Cheng6Bing Gao7Jun Chen8Department of Oncology The Second Hospital of Dalian Medical University Dalian ChinaDepartment of Pathology and Forensics Dalian Medical University Dalian ChinaDepartment of Oncology The Second Hospital of Dalian Medical University Dalian ChinaDepartment of Oncology The Second Hospital of Dalian Medical University Dalian ChinaSchool of Bioengineering Dalian University of Technology Dalian ChinaDepartment of Oncology The Second Hospital of Dalian Medical University Dalian ChinaDepartment of Oncology The Third Hospital of Dalian Medical University Dalian ChinaDepartment of Oncology The Third Hospital of Dalian Medical University Dalian ChinaDepartment of Oncology The Second Hospital of Dalian Medical University Dalian ChinaAbstract Background Circulating tumor DNA (ctDNA) has potential as a specific, noninvasive, and cost‐effective new biomarker for patients with lung cancer. This study aimed to determine whether plasma ctDNA can be used to predict treatment outcomes in patients with lung cancer. Methods Pre‐ and in‐treatment blood samples were collected from 14 patients with lung cancer receiving chemotherapy. Based on next‐generation sequencing technology, we constructed a unique molecular identifier (UMI) library and performed targeted deep sequencing of 72 genes (15 000×). We used dVAF to evaluate the change level and trend of variant allele frequency (VAF). Results We identified MUC16, KMT2D, AMER1, and NTRK1 as the most‐frequently mutated genes in ctDNA associated with lung cancer. Furthermore, we showed that the change trend of dVAF in patients with lung cancer undergoing chemotherapy was closely related to the changes in both tumor volume and tumor biomarkers, including CEA, CA125, NSE, and CK (Cytokeratin). Moreover, the ctDNA analysis revealed disease progression of SCLC patients earlier than did computed tomography. Conclusions The dynamic detection of plasma ctDNA VAF has the potential value as a biomarker for evaluating the efficacy of chemotherapy in patients with SCLC and advanced NSCLC, and may predict the progression of lung cancer patients earlier than radiography.https://doi.org/10.1111/1759-7714.14230chemotherapycirculating tumor DNAlung cancerunique molecular identifiers |
| spellingShingle | Min Zhang Chao Huang Huan Zhou Dan Liu Runze Chen Xiuhua Li Ye Cheng Bing Gao Jun Chen Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer Thoracic Cancer chemotherapy circulating tumor DNA lung cancer unique molecular identifiers |
| title | Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer |
| title_full | Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer |
| title_fullStr | Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer |
| title_full_unstemmed | Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer |
| title_short | Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer |
| title_sort | circulating tumor dna predicts the outcome of chemotherapy in patients with lung cancer |
| topic | chemotherapy circulating tumor DNA lung cancer unique molecular identifiers |
| url | https://doi.org/10.1111/1759-7714.14230 |
| work_keys_str_mv | AT minzhang circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer AT chaohuang circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer AT huanzhou circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer AT danliu circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer AT runzechen circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer AT xiuhuali circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer AT yecheng circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer AT binggao circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer AT junchen circulatingtumordnapredictstheoutcomeofchemotherapyinpatientswithlungcancer |